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Abstract: Complicated skin and soft tissue infections (cSSTIs) represent the severe form of 
infectious disease that involves deeper soft tissues. Involvement of methicillin-resistant Staphy-
lococcus aureus (MRSA) further complicates cSSTI with increased hospitalization, health care 
costs, and overall mortality. Various international guidelines provide recommendations on the 
management of cSSTIs, with the inclusion of newer antibiotics. This literature-based review 
discusses the overall management of cSSTI, including appropriate use of antibiotics in clini-
cal practice. Successful treatment of cSSTIs starts with early and precise diagnosis, including 
identification of causative pathogen and its load, determination of infection severity, associated 
complications, and risk factors. The current standard-of-care for cSSTIs involves incision, 
drainage, surgical debridement, broad-spectrum antibiotic therapy, and supportive care. In recent 
years, the emergence of newer antibiotics (eg, ceftaroline, tigecycline, daptomycin, linezolid, etc) 
has provided clinicians wider options of antimicrobial therapy. Selection of antibiotics should 
be based on the drug characteristics, effectiveness, safety, and treatment costs, alongside other 
aspects such as host factors and local multidrug resistance rates. However, larger studies on 
newer antibiotics are warranted to refine the decision making on the appropriate antimicrobial 
therapy. Local Antimicrobial Stewardship Program strategies in health care settings could guide 
clinicians for early initiation of specific treatments to combat region-specific antimicrobial 
resistance, minimize adverse effects, and to improve outcomes such as reduction in Clostridium 
difficile infections. These strategies involving iv-to-oral switch, de-escalation to narrow-spectrum 
antibiotics, and dose optimization have an impact on the overall improvement of cSSTI therapy 
outcomes, especially in countries like Singapore that has a high disease burden.
Keywords: antibiotics, complicated skin and soft tissue infections, methicillin-resistant Staphy-
lococcus aureus, Singapore
Introduction
Skin and soft tissue infections (SSTIs) encompass a wide clinical spectrum of common 
infectious diseases that often require acute treatment and inpatient hospital admission. 
These infections have a heterogeneous manifestation and involve microbial infection 
of the epidermis, dermis, superficial fascia, subcutaneous tissues, and muscle in an 
increasing order of severity.1 Complicated SSTIs (cSSTIs) are the most severe, involv-
ing deeper soft tissues and include infective cellulitis, ulcer or wound site infections, 
surgical site infections, major abscesses, infected burns, skin ulcers, and diabetic foot 
ulcers.2 The US FDA in 2013 grouped all SSTIs under a unified term, Acute Bacte-
rial Skin and Skin Structure Infection (ABSSSI), which includes cellulitis/erysipelas, 
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wound infection, and major cutaneous abscesses. It is defined 
as a bacterial infection of the skin with a lesion size area of 
at least 75 cm2 (lesion size measured by the area of redness, 
edema, or induration).3
Staphylococcus aureus, an aerobic Gram-positive coccus, 
is the most dominant causative pathogen and has paramount 
epidemiological significance in cSSTI. Pseudomonas aeru-
ginosa, Escherichia coli, and Enterococcus spp. have also 
been identified as causes of cSSTI; however, these are not the 
predominant causative pathogens.4 The rampant emergence of 
methicillin-resistant S. aureus (MRSA) infections, endemic 
to several countries worldwide, has confounded the treatment 
of cSSTIs.5 Initially, as MRSA emerged (from 1961 to 1990), 
hospital-associated MRSA (HA-MRSA) predominated, but in 
recent years, preponderance of community-associated MRSA 
(CA-MRSA) in SSTIs is noted in the US and Europe.6,7 
Dense population and relatively greater indiscriminate use of 
antibiotics predisposes Asian countries to high prevalence of 
endemic MRSA with estimated proportions of up to 70%.8 A 
multinational surveillance study conducted across eight Asian 
countries, namely, Korea, Taiwan, Hong Kong, Thailand, the 
Philippines, Vietnam, India, and Sri Lanka, from September 
2004 to August 2006 showed increase in the emergence of 
CA-MRSA, with incidence ranging from 2.5% to 39%.9
The epidemiology of MRSA infections reflects the overall 
increasing burden of SSTIs worldwide.10,11 In Asia, variable 
rates of MRSA (7.3%–74%) are reported in patients with 
SSTIs tested positive for S. aureus.12–17 In Singapore, high 
rates of MRSA (35.3%) were reported among S. aureus 
isolates, generally comparable with Western countries 
(23.6%–73.8%).18,19 Also, the SSTI-associated nosocomial 
infections account for 7.2% of all hospital-associated (HA) 
infections, with S. aureus identified as the predominant 
pathogen (27%).20 MRSA is a common cause of nosocomial 
infections in Singapore with incidences of serious outbreaks 
reported in general hospitals and intensive care units.21–23 
Additionally, elderly patients and patients with skin lesions 
or dermatological conditions were noted with a higher risk of 
harboring MRSA.23 The looming danger of severe infectious 
diseases like cSSTIs and the associated microbial resistance 
are persuasive, underscoring the need for implementation 
of systematic surveillance of cSSTI in Singapore. Several 
international working groups provide guidance on the sur-
gical and pharmacological management of cSSTIs recom-
mending inclusion of recently approved newer antibiotics. 
However, local data from Singapore for the prudent use of 
antibiotics in cSSTIs are scanty. The review, therefore, aims 
to provide an overview of the microbiology, drug resistance 
issues, diagnosis, and the overall management of cSSTI. In 
particular, the review explores the current medical evidence 
for appropriate use of antimicrobials and current management 
strategies for cSSTIs to achieve the best clinical outcomes, 
with special focus on newer antibiotics, which are approved 
by US FDA after 2000.
Literature search methodology
An electronic search of PubMed was conducted to source 
relevant articles using a combination of MeSH terms “com-
plicated skin and skin structure infections”, “skin and soft 
tissue infections”, “Gram-positive pathogens”, “Staphylococ-
cus aureus”, “methicillin-resistant Staphylococcus aureus”, 
“MRSA”, “multi drug resistance”, “nosocomial infections”, 
and “community-acquired infections”. Relevant articles 
included randomized controlled trials, surveillance, outcome 
studies, and expert opinions. Bibliographies of relevant 
articles were manually screened to broaden the literature 
search. All articles were restricted to English language 
and no restrictions were set with respect to year or type of 
publication.
Microbiology of cSSTI
Invasion of pathogens through disruptions of skin or soft tis-
sue structure is the fundamental etiology of SSTIs and several 
local and systemic risk factors further increase vulnerability 
to cSSTIs (Table 1).24
S. aureus, P. aeruginosa, E. coli, Enterococcus spp., 
Enterobacter spp., Klebsiella spp., and b-Streptococcus 
are the frequently encountered pathogens causing SSTIs 
in hospitalized patients.19 cSSTIs may be monomicrobial 
or polymicrobial in nature with increased systemic inflam-
matory responses. Management of polymicrobial or mixed 
infections requires a multidrug approach that is effec-
tive against aerobic, anaerobic, and facultative bacteria.25 
 Diabetic patients are at twice the risk vs non-diabetics, for 
cSSTI-related hospitalizations.26 In cases where vascular 
circulation is compromised such as diabetic foot infection, 
or infection of ischemic or venous ulcers, the risk of poly-
microbial infections is high. These complications are more 
common in patients who had previously received antibiotics 
for chronic infections.27
Issues related to the emergence of 
multidrug-resistant cSSTI and pertinent 
clinical management issues
The empirical approach for the treatment of cSSTI uses 
a combination of surgical, supportive, and antimicrobial 
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therapies. However, a rise in antibiotic-resistant microorgan-
isms,27 particularly multidrug-resistant organisms, has com-
plicated the treatment of cSSTI. Among multidrug-resistant 
organisms, MRSA, vancomycin-resistant Enterococcus spp. 
(VRE), and extended-spectrum β-lactamase (ESBL)–produc-
ing isolates of E.coli and Klebsiella spp. have the highest 
occurrence.19 Factors contributing to the development of 
MRSA SSTIs are intravenous drug use, HIV seropositivity, 
MRSA colonization or previous infection, African-American 
race, indwelling devices, and previous antibiotics or hospi-
talizations.11,28 The strains of CA-MRSA are genetically and 
Table 1 Skin and soft tissue infections: risk factors and common causative pathogens
Risk factors
Local Systemic
•	 Soft tissue trauma
•	 Animal or human bites
•	 Burns
•	 Operative or highly contaminated wounds
•	 Diminished perfusion due to peripheral vascular disease, 
obesity
•	 Poor hygiene
•	 exposure to contaminated water
•	 Presence of foreign body (eg, piercing, tattoos)
•	 Venous insufficiency and stasis
•	 Poorly controlled diabetes mellitus
•	 Immunocompromised comorbidities (eg, HIv infection, cellular or humoral 
immune deficiencies)
•	 Concomitant drugs (ie, corticosteroids, cyclosporine)
•	 Sensory neuropathies
•	 Chronic systemic illness (eg, cirrhosis)
Infection or risk factor Causative pathogen
Abscess Staphylococcus aureus
Polymicrobial
Cellulitis S. aureus
GABHS
Associated with injection use S. aureus
Associated with water exposure Aeromonas hydrophila, Vibrio vulnificus, Mycobacterium marinum
Associated with animal bite Pasteurella multocida, Capnocytophaga canimorsus
Associated with human bite Human oral flora
Surgical site infections Anaerobes
Enterococcus spp.
Enterobacter spp.
Gram-negative bacilli
Staphylococcus spp.
Streptococcus spp.
Escherichia coli
Necrotizing fasciitis Monomicrobial:
S. pyogenes, S. aureus, Enterobacteriaceae, Bacteroides, and Peptostreptococcus species
Polymicrobial:
Clostridium perfringens, S. aureus, Pseudomonas aeruginosa
Myonecrosis C. perfringens
Recurrent hospital admissions MRSA
Diabetes S. aureus (MRSA and MSSA), GABHS, anaerobes, Gram-negative bacilli
Diabetic foot ulcers S. aureus, Enterococcus spp., Streptococcus spp.
P. aeruginosa, Enterobacter spp., Acinetobacter spp.
Bacteroides spp
Cirrhosis Campylobacter fetus, Klebsiella pneumoniae, E. coli, Capnocytophaga canimorsus, other 
Gram-negative bacilli, Vibrio vulnificus
Neutropenia Gram-negative bacilli, P. aeruginosa
Abbreviations: GABHS, group A β-hemolytic streptococci; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus.
phenotypically distinct from HA-MRSA, and hence possess 
a risk of infections having greater severity and easier trans-
mission of resistance.29 The presence of Panton-Valentine 
leucocidin, a cytolytic toxin, encoding genes in MRSA 
isolated from CA-SSTIs are postulated to play a significant 
role in the increased virulence of these strains and are asso-
ciated with tissue necrosis, and greater severity of local and 
systemic manifestations.5,29 The CA-MRSA strains also carry 
the staphylococcal cassette chromosome mec (SCCmec) 
genes (types IV and V) that confer resistance to methicillin 
and currently available β-lactam antimicrobial agents and aid 
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easy transfer of resistance between organisms.30 Although 
MRSA was considered to be chiefly an HA infection, recent 
evidence suggests rapid emergence of CA-MRSA even in 
hospital settings.31–33 This complex infection epidemiology 
trend has further complicated the selection of antibiotics for 
treatment of cSSTI.
Diagnosis of complicated skin and soft 
tissue infections
Accurate diagnosis involving assessment of complications, 
severity, and risk factors, followed by identification of 
causative microorganism is essential for the management 
of cSSTI.
Comprehensive diagnosis of cSSTIs often starts with a 
clinical history and findings from physical examination that 
help assess the severity of an infection followed by investi-
gation of causative microorganism and its load. The precise 
diagnosis subsequently guides the decision on prompt and 
appropriate treatments34,35 (Figure 1).
Standard laboratory investigations are performed to aug-
ment clinical assessment, especially for inpatients. In addition 
to the patient history, relevant risk factors such as recurrent 
hospital admissions, diabetes, neutropenia, bite wounds, and 
animal contacts should be taken into consideration, which 
may indicate the possible microorganism responsible for 
the infection.27 Complications likely related to cSSTIs such 
as lymphadenitis, myositis/necrotizing fasciitis, gangrene, 
osteomyelitis, bacteremia, endocarditis, septicemia, or sepsis 
must also be factored in during diagnosis.36 The presence 
of significant leucocytosis (or leucopenia) may potentially 
indicate sepsis syndrome, while elevated creatine kinase 
(CK) levels may be suggestive of myonecrosis caused by 
necrotizing fasciitis or a compartment syndrome.27,34 Radio-
logical examination and imaging aid investigations of deep 
tissue infections to assess site and size of infection and any 
vascular involvement that can guide surgical drainage pro-
cedures. Microbiological culture tests should be performed 
in all cases to differentiate MRSA cSSTIs from non-MRSA 
infections and thus refine the decision on the definitive 
antibiotics administration to minimize the risk of potential 
treatment failure.35,37
Accurate diagnosis of cSSTIs can be an indicator of 
appropriate referrals in addition to immediate hospitalization. 
Observation of limb-threatening infections in patients with 
diabetes should prompt urgent referral to a multidisciplinary 
team, including infectious disease experts, podiatry, and/or 
Figure 1 Diagnosis of complicated skin and soft tissue infections.
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surgical (eg, orthopedic, vascular) specialists for effective 
surgical consultation and appropriate antimicrobial use.34 
Surgical consultation might also be required in cases of 
infections such as necrotizing fasciitis, synergic gangrene, 
and osteomyelitis or septic arthritis.
Management of complicated skin and soft 
tissue infections
The three fundamental pillars of cSSTI management are 
surgical drainage with debridement where necessary, broad-
spectrum antibiotic therapy, and physiological supportive 
care (Table 2).27,31 These interventions together are neces-
sary to ensure effective cSSTIs management, especially for 
a disease with diverse clinical presentation and dynamic 
interplay of multiple microbial, host, and local factors. The 
goals of cSSTI treatment are source control, antimicrobial 
therapy, and organ supportive care. Source control achieved 
by debridement only facilitates wound healing process that 
may be managed further by pharmacological interventions.38
Surgical methods and supportive care
Exudates, fluid collections of abscess, and ulcerations are 
common features of cSSTIs. Therefore, aggressive surgical 
debridement of the necrotic/infected tissue using chemical or 
mechanical methods is preferred whenever feasible to arrest 
the spread of infection and promote wound healing (Table 2). 
Delay in definitive debridement of necrotizing soft tissue 
Table 2 Recommendations for antibiotic treatment of methicillin-resistant Staphylococcus aureus complicated skin and soft tissue 
infections
Guidelines Infection Recommended therapy
Infectious Diseases Society of 
America31
cSSTI (deeper soft-tissue infections, surgical/
traumatic wound infection, major abscesses, cellulitis, 
and infected ulcers and burns)
•	 Surgical debridement
•	 vancomycin, linezolid, daptomycin, telavancin, 
clindamycin
Non-purulent cellulitis •	 β-lactam antibiotic active against MRSA
Surgical Infection Society118 Complex abscesses with cellulitis and polymicrobial 
cSSTIs
•	 Incision and drainage (in case of abscess)
•	 vancomycin, clindamycin, linezolid, or 
erythromycin
Gruppo Italiano di Studio sulle 
Infezioni Gravi41
MRSA-related cSSTIs and severe surgical infections •	 Use of TNP/vAC (for deep surgical 
infections)
•	 vancomycin, teicoplanin, linezolid, tigecycline, 
daptomycin
Italian Society of Infectious 
Diseases and international
Society of Chemotherapy119
MRSA-related cSSTIs •	 early surgical treatment wherever feasible
•	 vancomycin, teicoplanin, linezolid, tigecycline, 
daptomycin
Spanish Society of 
Chemotherapy35,120
MRSA-related cSSTIs Linezolid, daptomycin, vancomycin, teicoplanin
British Society of Antimicrobial
Chemotherapy121
Severe cSSTI with MRSA Linezolid, daptomycin, vancomycin, teicoplanin
Abbreviations: cSSTIs, complicated skin and soft tissue infections; MRSA, methicillin-resistant Staphylococcus aureus; TNP/vAC, topical negative pressure/vacuum-assisted 
closure.
infections is known as the single most significant risk factor 
for death.39 Incision and drainage are performed for abscess 
and purulent infections.40 Other approaches include topical 
negative pressure (TNP) dressing for chronic infections or 
large wounds with excessive exudate,35,41 vacuum-assisted 
closure (as alternative for wound healing) especially for 
surgical wounds or post-surgical deep infections,41 thrombec-
tomy for infections involving septic venous thrombosis, and 
reconstructive revascularization for cases involving arterial 
vessel injuries.42 Supportive cares involving fluid resuscita-
tion, organs support, and nutritional management to maintain 
oxygenation and tissue perfusion are critical interventions in 
the clinical outcomes of these patients.35,39
Pharmacological management
Systemic antibiotic therapy against the causative pathogen 
remains the mainstay for treatment of cSSTIs. Antibiotics 
against S. aureus are recommended for all cases involv-
ing systemic presentations such as temperature >38°C or 
<36°C, tachypnea (>24 breaths per minute), tachycardia 
(>90 beats per minute), or white blood cell count (WBC) 
>12,000 or <400 cells/µL.40 Most eminent international 
guidelines recommend initial management with empirical 
antibiotic therapy against locally prevalent MRSA strains. 
The Infectious Diseases Society of America recommends 
bacterial culture assessment to aid the selection of antibiotics 
against the causative pathogens and initiate definitive therapy 
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for severe infection, non-responsiveness to the current line 
of antibiotics, or recurrent infections.40 The UK’s National 
Institute for Clinical Excellence also recommends monitoring 
of clinical progress and reassessment of treatment based on 
culture findings.43
The timing of initiation and choice of appropriate anti-
microbial therapy against the causative organism are critical 
determinants of treatment outcome. Delay in initiating treat-
ment within 8 hours of presentation of cSSTI is associated 
with longer hospital stays44 and lack of active antibiotic 
therapy within 48 hours of admission with treatment fail-
ure.45 The US FDA suggests evaluation of clinical response 
to antibiotics in ABSSSI within 48–72 hours after initiation 
of therapy to identify potential treatment failure.3 In a large 
study, treatment failure in 22.8% patients with cSSTIs was 
associated with an increased risk of mortality (OR: 2.91; 
95% CI: 2.34–3.62).46 Prolonged hospital stay or readmission 
and associated increase in health care cost due to inadequate 
initial antimicrobial therapy for cSSTI are also reported.46,47
Successful therapy requires clinical acumen of empiric 
and definitive treatment substantiated with knowledge of 
pharmacokinetic and pharmacodynamic properties of the 
antibiotics. Minimum inhibitory concentration (MIC) helps 
interpret susceptibility of the particular pathogen to the anti-
microbial agent and rising MICs is indicative of emerging 
resistance of the pathogen to antibiotics (Table 3). Hence, the 
antibiotic should achieve a concentration equal to or greater 
than MIC at the site of infection.35 Poor tissue penetration 
adversely impacts the clinical and microbiological treat-
ment outcomes and increases the risk of resistance among 
pathogens.48 Several factors such as vascular insufficiency or 
presence of comorbid diabetes or vascular diseases predomi-
nant in cSSTIs are known to interfere with antibiotic tissue 
penetration, thus restricting their efficacy.49,50 Hence, for 
antibiotic selection, a careful evaluation of the key determi-
nants of a drug’s tissue penetration like the molecular weight, 
lipophilicity, tissue to plasma penetration ratio, protein bind-
ing, and volume of distribution is recommended.35,51,52
Older antibiotics
Vancomycin is effective against susceptible Gram-positive 
bacteria including MRSA,53 and has shown comparable 
efficacy to newer agents (linezolid, daptomycin, tigecy-
cline); however, poor tissue penetration (8%–10%) lowers 
its efficacy in severe cases of cSSTIs53 (Table 4). The risk 
of nephrotoxicity and complications necessitates the need 
for dose titration in the special population with impaired 
renal function.54 Clindamycin, active against MRSA, has 
good tissue penetration (97%) and tolerability profile, and 
the ability to inhibit production of bacterial toxins com-
mon in CA-MRSA infection.27 However, development of 
Clostridium difficile-associated colitis requires monitor-
ing during therapy.55 The use of penicillin derivatives and 
β-lactamase inhibitors (cloxacillin, amoxicillin/clavulanic 
acid) is discouraged in most cSSTIs cases due to lack of 
efficacy against MRSA infections. Also, fosfomycin and 
quinupristin/dalfopristin for cSSTIs use are challenged due 
to safety concerns of hepatic dysfunction, severe myalgia, 
and rapid emergence of resistance.53,56 Inadequate evidence 
from controlled studies demonstrating efficacy and safety 
of older antibiotics for cSSTI also limit their clinical use.53 
With the advent of life-threatening MRSA and CA-cSSTIs, 
streamlining the use of available and effective antimicrobi-
als becomes obligatory. Several national and international 
treatment guidelines have revisited the evidence to provide 
recommendations for antimicrobial therapy (Table 2).35
Newer antibiotics
Newer antibiotics (refers to antibiotics which are approved by 
US FDA from 2000 onward) provide clinicians good oppor-
tunities to overcome current challenges in the management 
and treatment of MRSA infections (Table 4).
1. Linezolid, an oxazolidinone, is a newer alternative to 
glycopeptide antimicrobials, approved for use in serious 
cSSTIs caused by MRSA and VRE (US FDA approval: 
April 2000). It also inhibits bacterial exotoxins production 
that aggravates the severity of CA-MRSA infections.27 
Linezolid has demonstrated high clinical cure rates and 
non-inferiority to oxacillin/dicloxacillin in the treatment 
of cSSTIs, including cellulitis, skin abscesses, erysipelas, 
and surgical infections.57 Linezolid also showed higher 
cure rates than vancomycin (67% vs 62%) against sus-
pected MRSA-associated cSSTIs, and more recently, 
has demonstrated superior clinical and microbiological 
outcomes vs vancomycin.58–60 In addition, equivalent oral 
bioavailability of linezolid offers a pragmatic advantage 
that facilitates shorter iv therapy and early hospital 
discharge.60 Several studies have shown linezolid to be 
safe; however, in post-marketing studies, prolonged use 
of linezolid was associated with neuropathy (peripheral 
or optical), hematological abnormalities (particularly 
thrombocytopenia or anemia), and hyperlactatemia.61
2. Daptomycin, a cyclic lipopeptide approved for use in 
cSSTIs has shown adequate clinical activity against 
MRSA and VRE (US FDA approval: December 2003). 
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Table 3 Minimum inhibitory concentration of antibiotics used for cSSTIs (european Committee on Antimicrobial Susceptibility Testing)
Drug Pathogens Minimum inhibitory concentrations (µg/mL)
Susceptible £ Resistant >
Older Antibiotics
vancomycin Staphylococcus aureus 2 2
Coagulase-negative staphylococci 4 4
Enterococcus spp. 4 4
Streptococcus groups A, B, C, and G 2 2
Streptococcus pneumoniae 2 2
viridans group streptococci 2 2
Gram-positive anaerobes except Clostridium difficile 2 2
C. difficile 2 2
Corynebacterium spp. 2 2
Aerococcus sanguinicola and urinae 1 1
Amoxicillin/ clavulanic acid Enterococcus spp. 4 8
viridans group streptococci 0.5 2
Haemophilus influenzae 2 2
Neisseria meningitidis 0.125 1
Gram-positive anaerobes except C. difficile 4 8
Gram-negative anaerobes 0.5 2
Helicobacter pylori 0.125 0.125
Pasteurella multocida 1 1
Kingella kingae 0.125 0.125
Enterobacteriaceae 8 8
Enterococcus spp. 4 8
Clindamycin Staphylococcus spp. 0.25 0.5
Streptococcus groups A, B, C, and G 0.5 0.5
S. pneumoniae 0.5 0.5
viridans group streptococci 0.5 0.5
Gram-positive anaerobes except C. difficile 4 4
Gram-negative anaerobes 4 4
Corynebacterium spp. 0.5 0.5
Teicoplanin Enterococcus spp. 2 2
Streptococcus groups A, B, C, and G 2 2
S. pneumoniae 2 2
viridans group streptococci 2 2
Staphylococcus spp. 2 2
Coagulase-negative staphylococci 4 4
Newer antibiotics**
Linezolid Staphylococcus spp. 4 4
Enterococcus spp. 4 4
Streptococcus groups A, B, C, and G 2 4
S. pneumoniae 2 4
Corynebacterium spp. 2 2
Daptomycin Streptococcus groups A, B, C, and G 1 1
Staphylococcus spp. 1 1
Tigecycline enterobacteriaceae 1 2
Staphylococcus spp. 0.5 0.5
Enterococcus spp. 0.25 0.5
Streptococcus groups A, B, C, and G 0.25 0.5
Ceftaroline S. pneumoniae 0.25 0.25
Haemophilus influenzae 0.03 0.03
Enterobacteriaceae 0.5 0.5
Staphylococcus spp., S. aureus 1 1
Tedizolid Staphylococcus spp. 0.5 0.5
Streptococcus groups A, B, C, and G
viridans group streptococci (S. anginosus group) 0.25 0.25
Dalbavancin* viridans group streptococci (S. anginosus group) 0.125 0.125
Staphylococcus spp. 0.125 0.125
Streptococcus groups A, B, C, and G 0.125 0.125
Oritavancin* viridans group streptococci (S. anginosus group) 0.25 0.25
Staphylococcus spp. (S. aureus) 0.125 0.125
Streptococcus groups A, B, C, and G 0.25 0.25
Notes: *Dalbavancin and oritavancin are not approved in Singapore. **“Newer antibiotics” refers to antibiotics which are approved by US  FDA from 2000 onward. 
These data have been produced in part under eCDC service contracts and made available by eUCAST at no cost to the user and can be accessed on the eUCAST website 
www.eucast.org. eUCAST recommendations are frequently updated and the latest versions are available at www.eucast.org.
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 Real-world data collected across wide geographical 
regions (US, Europe, Latin America, and Asia) demon-
strated high clinical success rates (81%) with daptomycin 
for cSSTIs.62 Daptomycin showed non-inferiority to van-
comycin and semi-synthetic penicillins in the treatment 
of cSSTIs.63 In an open-label study, 77% of 53 cSSTIs 
patients treated with daptomycin achieved complete reso-
lution of infection (vs 42% of 221 patients on vancomy-
cin) with rapid symptom resolution in a shorter inpatient 
treatment course.64 The overall efficacy and safety, with 
the practical advantage of a once-daily intravenous (iv) 
regimen, supports the use of daptomycin in cSSTIs.65,66 
Overall, daptomycin has a good safety profile; however, 
clinical studies have reported elevations in creatine 
phosphokinase and associated muscle toxicity. Therefore, 
monitoring of laboratory abnormalities is recommended 
during treatment.67
3. Tigecycline, a tetracycline-related antimicrobial, is an 
advantageous empiric treatment option for cSSTIs (US 
FDA approval: June 2005). In 2013, the US FDA issued 
a black box warning of increased risk of mortality of 
tigecycline vs comparator drugs. However, tigecycline 
may likely be considered instead of combination therapy, 
where this is deemed necessary, due to its broad-spectrum 
activity (Table 4).68
4. Ceftaroline, a new generation cephalosporin with clini-
cally meaningful activity against MRSA, is approved 
for the treatment of cSSTIs and community-acquired 
pneumonia (US FDA approval: October 2010). Over 
90% of MRSA isolates were found to be susceptible to 
ceftaroline in US, Europe, Middle East, and Africa with 
MICs ranging from 0.25 to 4 mg/L. Ceftaroline has 
also shown potent antimicrobial activity against a large 
number of SSTI-associated bacterial isolates including 
MRSA (80.6% susceptibility) from South Africa and 
Asia-Pacific region.69 The pharmacodynamic profile of 
ceftaroline 600 mg every 8 hours (q8h) and every 12 
hours (q12h) infusion was generally comparable and is 
adequate for the effective eradication of MRSA. The q8h 
infusion treatment had a higher probability of attaining 
MIC of 4 mg/L; however, this treatment approach has 
limited evidence from clinical studies and is yet to receive 
approval in this region. The safety profile of ceftaroline 
was consistent with cephalosporin class. The most com-
mon adverse events observed were diarrhea, nausea, and 
rash.70 Administration of ceftaroline demonstrated no 
significant effect on the intestinal flora in healthy par-
ticipants, and thus, risk of C. difficile-related diarrhea is 
low.71 Ceftaroline (q12 dosing schedule) is a viable option 
in the armamentarium of antibiotics for treating cSSTIs 
due to Gram-negative and Gram-positive (with MRSA) 
infections or following failure of vancomycin therapy 
(Table 4).72 Studies with a q8h dosing of ceftaroline are 
ongoing; if the findings are conducive, this dosing may 
become a better alternative than the standard dose, espe-
cially in areas of high MRSA endemicity.
5. Tedizolid, another novel oxazolidinone is approved for 
use in ABSSSI due to MRSA (US FDA approval: June 
2014).73 In two Phase III studies of ABSSSI, a 6-day 
course with tedizolid was significantly non-inferior to 
a 10-day linezolid course for an early clinical response 
(48–72 hour after treatment initiation).74 A better toler-
ability profile (few gastrointestinal adverse events, lower 
myelotoxicity risk) and an option of iv-to-oral switch 
make tedizolid a valuable treatment choice for manage-
ment of cSSTIs.74 The oxazolidinones are particularly 
helpful for the treatment of necrotizing fasciitis since they 
inhibit the production of bacterial pyrogenic endotoxins.75
6. Oritavancin and dalbavancin are lipoglycopeptides 
(approved by US FDA in 2014) with the pharmacokinetic 
advantage of extended plasma half-life, enabling single-
dose regimens.68 These antibiotics are yet to receive 
approval in Singapore. Oritavancin, a derivative of vanco-
mycin, has extended bactericidal activity against MRSA 
and daptomycin non-susceptible VRE. Single iv dose, 
oritavancin, was non-inferior to twice-daily vancomycin 
(7-to-10 day course) in two Phase III studies of ABSSSI 
caused by Gram-positive pathogens.76,77 Dalbavancin, 
a derivative of a teicoplanin-like natural antibiotic has 
antimicrobial activity against almost all clinical MRSA 
isolates. Once-weekly iv dalbavancin was non-inferior to 
twice-daily vancomycin followed by oral linezolid with 
comparable success rates in ABSSSI as demonstrated in 
a pooled analysis.78 Dalbavancin and oritavancin has a 
similar safety profile as vancomycin. In clinical studies, 
the most commonly reported adverse events were head-
ache, nausea, diarrhea, and vomiting.79 The elimination 
of multidose and multiday regimen and lower propensity 
for resistance development are potential benefits of dalba-
vancin and oritavancin treatments. However, the absence 
of de-escalation, high-cost acquisition, and limited clini-
cal evidence for these agents is noteworthy.68
Intravenous-to-oral switch
For the rapid attainment of desired serum therapeutic levels, 
parenteral antibacterial therapy is recommended for cSSTIs 
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in hospitalized or ambulatory care settings.34 Oral formula-
tions with convenient dosing and administration at home offer 
effective outpatient management, allow a seamless transition 
of continued care, and recovery. Potent antibiotics with high 
oral bioavailability offer an additional advantage without 
compromising clinical efficacy (eg, linezolid, tedizolid). The 
key advantage of iv-to-oral switch is early hospital discharge, 
which from a physician’s perspective lowers risks of HA 
complications and infections.35,80 From a patient’s perspective 
it results in reduced isolation, early recovery, and improved 
quality-of-life.35,81 The critical decision of switching a patient 
from iv-to-oral therapy depends on the patient’s ability to 
tolerate the switch and on the microbiological etiology.82 
Afebrile (>24 hours) patients with clinically stable infection, 
normalized WBC count (<4×109/L or >12×109/L), no cardio-
vascular abnormality (no tachycardia and systolic blood pres-
sure ≥100 mgHg) and who have received iv antibiotic therapy 
for >24 hours can be switched to oral therapy. Patients should 
be able to tolerate oral fluids or diet to allow administration of 
oral medications with no gastrointestinal complications.35,83 
The switch to oral therapy is contraindicated in patients with 
severe vomiting and diarrhea, hematological malignancies or 
neutropenia, impaired gastrointestinal absorption, dementia, 
and severe infections of the musculoskeletal, central nervous 
system, or vascular systems.35,83 Presence of comorbidities, 
unavailability of caregiver, and an advancing age may com-
monly delay oral switch and hospital discharge.35
De-escalation strategy
Antibiotic de-escalation is a scheme of utilizing a discreet 
antibiotic regimen to avoid indiscriminate antibiotic use that 
increases the risk of resistance.84 The de-escalation strategy 
can be implemented by switching from empirical broad-
spectrum antimicrobials to a narrower-spectrum or targeted 
treatment after a systematic reassessment.85 Currently, the 
acceptable approach is the timely initiation of antibiotic 
therapy that provides appropriate coverage for key patho-
gens including resistant strains, followed by a de-escalation 
approach on the availability of susceptibility results to 
avoid prolonged exposure to a broader-spectrum antibiotic 
therapy.84 Available evidence indicates that antibiotic de-
escalation has no safety concerns, showed improved clinical 
outcomes (based on microbiological data, novel inflammatory 
markers), lesser antibiotic resistance profiles, and lowered 
chances of recurrent infections along with substantial reduc-
tions in adverse effects of non-judicious use of antibiotics.86,87
The de-escalation strategy aims to reduce costs and dura-
tion of hospitalization by switching from empiric antibiotics 
to definitive culture-directed agents, curbing unnecessary or 
redundant treatment, and switching from iv to oral therapy. 
This switch to oral therapy also results in direct cost savings 
(supplies, nursing time, cost-effective drug), lowers risk of 
line infections (via the catheters), and increases the patient’s 
mobility, thereby reducing the duration of hospital stay.88 
Protocols that guide transitioning to more effective anti-
microbials with reduced toxicity (eg, β-lactams instead of 
vancomycin for confirmed MSSA) may ease selection pres-
sures and help achieve appropriate and safe de-escalations 
for critical infections.89 The duration of antibiotic use (less 
by 2 days) and the length of stay were significantly reduced 
in patients with ABSSSIs subjected to Antimicrobial Stew-
ardship Program (ASP)-based intervention. The reduction 
in length of hospital stay culminated into a substantial cost 
reduction.90
Development of C. difficile-associated diarrhea follow-
ing exposure to most antibiotics is a more predominant 
public health problem as compared with antimicrobial 
resistance.91 Therefore, another critical target for ASP should 
be preventing infection or restricting nosocomial infections 
with  C  difficile in susceptible individuals. The incidence of 
C.  difficile infections can be considerably lowered by optimiz-
ing the selection of antibiotics (eg, possibly substitution with 
newer cephalosporins like ceftaroline), dosing, de-escalation, 
and duration of therapy.88,91
Antimicrobial stewardship program
ASP is a strategy to improve the current antibiotic prescrip-
tion practice through education of prescribers, development 
of antimicrobial formulary, and review-feedback process of 
the prescription pattern for prescribers.92,93 Excessive or indis-
criminate use of antibiotics, particularly the broad-spectrum 
antibiotics, is associated with the emergence of antibiotic-
resistant bacteria such as ESBL-producing Gram-negative 
bacteria, MRSA, and development of C. difficile infections. A 
multifaceted strategy is required to combat the antimicrobial 
resistance. ASP, a multidisciplinary approach, encourages 
various measures, including optimization of prescribing 
practice. It mainly aims to improve the clinical outcomes 
of antibiotic use, minimize the adverse effects, and impede 
the development of antimicrobial resistance and C. difficile 
infections.94 Several countries have successfully adopted ASP 
in hospital settings based on the WHO Global Action Plan 
(mandated in May 2015) to tackle antimicrobial resistance.95 
ASPs implemented by the National Health Service (NHS) 
across the UK utilizes “Start Smart-Then Focus” approach 
to improve prudent use of antibiotics.94,96 It comprises several 
strategies, including implementation of evidence-based local 
prescribing guidelines relevant to local health care setting and 
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antibiotic resistance pattern, iv-to-oral switch, de-escalation, 
dose optimization, quality assurance audits, education, and 
training.96 These strategies have substantially supported the 
improvement in discreet antibiotic usage, reduced length of 
hospital stay, and improved clinical outcomes, such as reduc-
tions in C. difficile infections.97,98 Hospital settings in Singa-
pore employ a similar ASP model of iv-to-oral switch and 
de-escalation. A 3-year retrospective review from Singapore 
General Hospital revealed that patients with ABSSSI had an 
acceptance rate of 66% for the interventions recommended by 
the ASP and these interventions caused no safety concerns.99 
Nevertheless, to improve the overall success in hospital stays 
and for patient safety, regular review and upgrading of ASPs 
with a holistic health care approach is advisable.
Nursing and postoperative wound 
management
Optimal management of wounds is critical to prevent 
potential complications in postoperative surgical sites or 
dehiscence of the surgical wounds and improve recovery 
with appropriate functional and esthetic results in patients 
with cSSTIs.100 Wound dressings aid wound healing by 
maintaining a moist environment (accentuates wound 
re-epithelization and healing), provide a barrier against 
bacterial or fluid contamination, and help in the removal 
of excessive exudate (by absorbing, gelling, and transfer of 
fluid away from the wound bed), preventing likely wound 
maceration (Figure 2).100,101
Advanced therapies in the wound management such as 
silver compound dressing and negative wound pressure treat-
ment may improve the wound care by decreasing the chances 
of reinfection and help in the removal of exudate, reduction of 
lateral incision tension, and reduction of hematoma or seroma 
formation.43,102–104 Silver and silver compounds have broad-
spectrum bactericidal properties and have been used effectively 
as wound dressings.105 Sustained-release silver dressings, 
silver-donating nanocrystalline dressings, and antimicrobial 
negative-pressure dressing (NPD) with silver have proven 
to be effective in promoting wound  healings.106–108 Use of 
silver-based dressing in packing abscess cavities after incision 
and drainage treatment may cause faster healing along with 
improvements in pain intensity.109 Silver dressings have proven 
to be safe and effective as compared to normal gauze dress-
ings in preventing postoperative surgical site infections.106,110
Physical methods of exudate control in infected post-
surgical wounds such as negative wound pressure therapy or a 
combination of a silver antimicrobial NPD have demonstrated 
to improve healing outcomes along with decreased nursing 
time and reduced cost.41,111,112 In cases of minor dehiscence, 
secondary closure of wounds following removal of necrotic 
tissue must be opted. For severe dehiscence, TNP therapy 
following local debridement is recommended.100 Selection 
Figure 2 Nursing and postoperative care in complicated skin and soft tissue infections.
Wound dressing
Provides moist environment for wound healing
Barrier against bacterial contamination
Removal of exudates
Antimicrobial dressings: preferred in excess exudate with bacterial infection
Silver/silver compound dressing
Bactericidal agents
Broad-spectrum
Sustained-release dressing
Nanocrystalline silver dressing: reduces inflammation by lowering levels of proteolytic
enzymes that delay wound healing
Silver antimicrobial + negative pressure dressing: management of superficial to partial-
thickness burns, wounds, abrasions, traumatic wounds, surgical wounds, dehisced
wounds, diabetic ulcers, and venous ulcers
Physical methods
Negative pressure wound therapy (for heavily exudating wounds): reduces edema,
improves tissue perfusion by reducing size and complexity of wound
Silver antimicrobial negative pressure dressing + negative pressure wound
therapy: improved healing 
Secondary wound closure: minor dehiscence of surgical wounds
Topical negative pressure: severe dehiscence of surgical wounds
Infection and Drug Resistance 2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1970
Leong et al
of appropriate methods of cleansing and dressing along with 
prompt intervention of wound complications holds the key 
to effective wound management.
Future directions
A myriad of antibiotics is already available and a number 
of novel ones have been or are being developed for the 
management of cSSTIs. Clear differentiation, in terms of 
therapy outcomes, among these newer agents is hampered 
by the lack of robust clinical data on head-to-head compari-
son between these antibiotics. Although newer antibiotics 
may confer several advantages over older agents, they are 
in general expensive and less accessible. Furthermore, data 
regarding their usage in special populations, eg, diabetic 
foot infections, peripheral vascular disease, etc, is inad-
equate.113 Special indications for these newer agents such 
as oxazolidinones can be regarded as preferred agents for 
necrotizing fasciitis because they inhibit bacterial toxin 
production.75 Ceftaroline offers additional advantages with 
possible lower risk for C. difficile infection. Additionally, 
there are emerging data on combination with older antibi-
otics to achieve synergistic efficacy and cost-effectiveness 
in therapy. Studies exploring vancomycin and beta-lactam 
combinations for MRSA have demonstrated shortening of 
the duration of MRSA bacteremia.114,115 Nonetheless, larger 
sample size, double-blind, adequately powered future trials 
with clinically relevant end points for newer antibiotics and 
newer combinations of antibiotics for cSSTIs are required 
to fill the information gaps for clinicians to augment deci-
sion making.116 Real-world evidence would further add to 
the information on safety, efficacy, and cost-effectiveness of 
these therapies for cSSTI management.117 In short, a prudent 
clinical decision on the selection of the most appropriate 
pharmacological agent or agents would be based on their 
efficacy, safety profile, tolerability, cost-effectiveness, acces-
sibility, and practicability.
Conclusion
In the light of epidemiological shift in global prevalence of 
MRSA and associated cSSTIs, clinicians need to constantly 
challenge and review the existing clinical guidelines and 
practices. With the emergence of newer antibiotics and cur-
rent medical evidence in clinical practice, optimal clinical 
usage needs to be determined. Decision on the choice of 
antimicrobial therapy for cSSTI is guided by both scientific 
data and clinical experience. Multiple factors, including host 
factors, local multidrug resistance data, cost consideration, 
and drug characteristics, have to be considered holistically 
in the management of cSSTIs. Often, the outcomes, despite 
prudent clinical judgment, remain unpredictable. Simply, 
other factors at play that may not be within the clinician’s 
scope of knowledge could also impact treatment outcomes. 
Local ASP strategies in health care institutions would guide 
clinicians in early initiation of specific treatments to combat 
region-specific CA-MRSA infections. Hence, adopting well-
tested approaches such as iv-to-oral switch, regular review 
of clinical response, de-escalation to narrow-spectrum anti-
biotics to reduce the length of hospital stay, hospital-related 
complications, and overall treatment expenses can modify 
the paradigm and the clinical outcomes for management of 
cSSTIs in countries like Singapore.
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